0.6799
1.48%
+0.0099
After Hours:
.6512
-0.0287
-4.22%
Lipella Pharmaceuticals Inc stock is currently priced at $0.6799, with a 24-hour trading volume of 8,341.
It has seen a +1.48% increased in the last 24 hours and a -9.35% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.6653 pivot point. If it approaches the $0.6847 resistance level, significant changes may occur.
Previous Close:
$0.67
Open:
$0.65
24h Volume:
8,341
Market Cap:
$5.17M
Revenue:
-
Net Income/Loss:
$-4.62M
P/E Ratio:
-1.0499
EPS:
-0.6476
Net Cash Flow:
$-3.15M
1W Performance:
+3.85%
1M Performance:
-9.35%
6M Performance:
-30.20%
1Y Performance:
-68.95%
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
Name
Lipella Pharmaceuticals Inc
Sector
Industry
Phone
412-894-1853
Address
7800 Susquehanna St., Suite 505, Pittsburgh
Lipella Pharmaceuticals Inc Stock (LIPO) Latest News
Lipella Pharmaceuticals (NASDAQ:LIPO) Trading 1.6% Higher - Defense World
Defense World
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of ... - WDRB
WDRB
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus - GlobeNewswire
GlobeNewswire
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
GlobeNewswire Inc.
Ratios Reveal: Breaking Down Lipella Pharmaceuticals Inc (LIPO)'s Financial Health – DWinneX - The Dwinnex
The Dwinnex
LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024 - MSN
MSN
Lipella Pharmaceuticals Inc Stock (LIPO) Financials Data
Lipella Pharmaceuticals Inc (LIPO) Net Income 2024
LIPO net income (TTM) was -$4.62 million for the quarter ending December 31, 2023, a -77.81% decrease year-over-year.
Lipella Pharmaceuticals Inc (LIPO) Cash Flow 2024
LIPO recorded a free cash flow (TTM) of -$3.15 million for the quarter ending December 31, 2023, a -72.03% decrease year-over-year.
Lipella Pharmaceuticals Inc (LIPO) Earnings per Share 2024
LIPO earnings per share (TTM) was -$0.78 for the quarter ending December 31, 2023, a -72.49% decline year-over-year.
About Lipella Pharmaceuticals Inc
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Cap:
|
Volume (24h):